trimetrexate has been researched along with Liver Neoplasms in 6 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Liver Neoplasms: Tumors or cancer of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-two patients with previously untreated metastatic breast cancer and nineteen patients with refractory metastatic breast cancer were treated with trimetrexate (TMTX)." | 9.07 | Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study. ( Carey, RW; Clamon, GH; Costanza, ME; Dawson, NA; Korzun, AH; Norton, L; Pollak, M; Vogelzang, NJ, 1991) |
| "Therapeutic options after failure of 5-fluorouracil (5-FU) for the treatment of colorectal cancer include regional treatments, different 5-FU-based regimens, and different chemotherapy regimens." | 8.80 | Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure. ( Henderson, CA, 1998) |
| "The purpose of this report is to evaluate the efficacy and toxicity (Tx) of a double modulation of 5-fluorouracil (5-FU) by trimetrexate (TMTX) and leucovorin (LV) in patients with advanced recurrent (inoperable) or metastatic colorectal cancer (ACC)." | 5.11 | Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma. ( Bologna, F; Dominguez, ME; Lacava, JA; Leone, BA; Machiavelli, MR; Ortiz, EH; Pérez, JE; Romero, AO; Salum, G; Vallejo, CT, 2004) |
| "Twenty-two patients with previously untreated metastatic breast cancer and nineteen patients with refractory metastatic breast cancer were treated with trimetrexate (TMTX)." | 5.07 | Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study. ( Carey, RW; Clamon, GH; Costanza, ME; Dawson, NA; Korzun, AH; Norton, L; Pollak, M; Vogelzang, NJ, 1991) |
| "Therapeutic options after failure of 5-fluorouracil (5-FU) for the treatment of colorectal cancer include regional treatments, different 5-FU-based regimens, and different chemotherapy regimens." | 4.80 | Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure. ( Henderson, CA, 1998) |
| "In four phase II trials of trimetrexate given iv daily for 5 days, we noted marked variability among patients in the development of severe or life-threatening toxic effects." | 1.27 | Trimetrexate: predictors of severe or life-threatening toxic effects. ( Eisenhauer, EA; Pater, JL; Walsh, WR; Zee, BC, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Machiavelli, MR | 1 |
| Salum, G | 1 |
| Pérez, JE | 1 |
| Ortiz, EH | 1 |
| Romero, AO | 1 |
| Bologna, F | 1 |
| Vallejo, CT | 1 |
| Lacava, JA | 1 |
| Dominguez, ME | 1 |
| Leone, BA | 1 |
| Harvey, WH | 1 |
| Fleming, TR | 1 |
| Goodman, PJ | 1 |
| Harvey, JH | 1 |
| Rivkin, SE | 1 |
| MacDonald, JS | 1 |
| Henderson, CA | 1 |
| Dawson, NA | 1 |
| Costanza, ME | 1 |
| Korzun, AH | 1 |
| Clamon, GH | 1 |
| Pollak, M | 1 |
| Vogelzang, NJ | 1 |
| Carey, RW | 1 |
| Norton, L | 1 |
| Rhee, MS | 1 |
| Balinska, M | 1 |
| Bunni, M | 1 |
| Priest, DG | 1 |
| Maley, GF | 1 |
| Maley, F | 1 |
| Galivan, J | 1 |
| Eisenhauer, EA | 1 |
| Zee, BC | 1 |
| Pater, JL | 1 |
| Walsh, WR | 1 |
1 review available for trimetrexate and Liver Neoplasms
| Article | Year |
|---|---|
Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 1998 |
3 trials available for trimetrexate and Liver Neoplasms
| Article | Year |
|---|---|
Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 2004 |
Phase II study of trimetrexate in previously untreated patients with hepatocellular carcinoma. Southwest Oncology Group study 8712.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Drugs, Investigational; Female; Humans; I | 1993 |
Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; | 1991 |
2 other studies available for trimetrexate and Liver Neoplasms
| Article | Year |
|---|---|
Role of substrate depletion in the inhibition of thymidylate biosynthesis by the dihydrofolate reductase inhibitor trimetrexate in cultured hepatoma cells.
Topics: Carcinoma, Hepatocellular; Folic Acid; Liver Neoplasms; Pteroylpolyglutamic Acids; Quinazolines; Thy | 1990 |
Trimetrexate: predictors of severe or life-threatening toxic effects.
Topics: Antineoplastic Agents; Blood Proteins; Drug Evaluation; Female; Folic Acid Antagonists; Humans; Live | 1988 |